LifeCell International is a prominent Indian biotechnology company founded in 2004, primarily known for its extensive work in stem cell banking and related healthcare services. Company OverviewFoundation: Established in 2004, LifeCell International has become India's largest stem cell bank and is recognized as the third-largest globally.Core Services: The company specializes in umbilical cord blood stem cell banking, diagnostics, and tissue therapeutics. It aims to provide preventive healthcare services that enhance family wellness
| P&L Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 170.75 | 137.16 | 166.92 | - |
| Cost of Material Consumed | - | - | - | - |
| Gross Margins | - | - | - | - |
| Change in Inventory | - | - | - | - |
| Employee Benefit Expenses | - | - | - | - |
| Other Expenses | - | - | - | - |
| EBITDA | 14.11 | -22.62 | 92 | - |
| OPM | - | - | 55.12% | - |
| Other Income | - | - | - | - |
| Finance Cost | - | - | - | - |
| D&A | - | - | - | - |
| EBIT | - | - | - | - |
| EBIT Margins | - | - | - | - |
| PBT | 107.31 | -12.23 | 92 | - |
| PBT Margins | 37.15% | -4.55% | 55.12% | - |
| Tax (2021) | - | - | - | - |
| PAT | 107.31 | -11.56 | 92 | - |
| NPM | 37.15% | -108.43% | 55.12% | - |
| EPS | - | - | - | - |
| Financial Ratios | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | - | - | - | - |
| Net Profit Margin | 37.15% | -4.55% | 55.12% | - |
| Earning Per Share (Diluted) | - | - | - | - |
| Assets | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Fixed Assets | - | - | - | - |
| CWIP | - | - | - | - |
| Investments | 90.51 | - | - | - |
| Trade Receivables | - | - | - | - |
| Inventory | - | - | - | - |
| Other Assets | - | - | - | - |
| Total Assets | - | - | - | - |
| Liabilities | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Share Capital | 7.2 | 7.2 | 7.2 | - |
| FV | - | - | - | - |
| Reserves | - | - | - | - |
| Borrowings | - | - | - | - |
| Trade Payables | - | - | - | - |
| Other Liabilities | - | - | - | - |
| Total Liabilities | - | - | - | - |
| Cash-Flow Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| PBT | - | - | - | - |
| OPBWC | - | - | - | - |
| Change in Receivables | - | - | - | - |
| Change in Inventories | - | - | - | - |
| Change in Payables | - | - | - | - |
| Other Changes | - | - | - | - |
| Working Capital Change | - | - | - | - |
| Cash Generated From Operations | - | - | - | - |
| Tax | - | - | - | - |
| Cash Flow From Operations | - | - | - | - |
| Purchase of PPE | - | - | - | - |
| Sale of PPE | - | - | - | - |
| Cash Flow From Investment | - | - | - | - |
| Borrowing | - | - | - | - |
| Divided | - | - | - | - |
| Equity | - | - | - | - |
| Others From Financing | - | - | - | - |
| Cash Flow from Financing | - | - | - | - |
| Net Cash Generated | - | - | - | - |
| Cash at the Start | - | - | - | - |
| Cash at the End | - | - | - | - |
| Shareholding Pattern | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Individuals | 91.59% | - | - | - |
| Foreign Holding | 8.41% | - | - | - |
